- The first participants have been dosed in a Phase 2 clinical trial evaluating Appili Therapeutics' (OTCQX:APLIF) favipiravir as a preventative measure against COVID-19 outbreaks in long-term care (LTC) facilities.
- The trial will include elderly subjects with comorbidities at 16 LTC centers and front-line healthcare workers with recent COVID-19 exposure or confirmed infection.
- The primary endpoint is the control of the outbreak, defined as no new microbiologically confirmed cases of COVID-19 for at least 24 consecutive days.
- Favipiravir is an orally administered broad-spectrum antiviral developed by FUJIFILM Toyama Chemical. It is sold in Japan under the brand name Avigan for the treatment of influenza and as a stockpile countermeasure against pandemic influenza.
- Topline data should be available in 2021.
- https://seekingalpha.com/news/3623597-mid-stage-study-of-appili-therapeutics-favipiravir-in-covidminus-19-underway
Tuesday, October 20, 2020
Mid-stage study of Appili Therapeutics' favipiravir in COVID-19 underway
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.